北醫藥學院教師研究專長簡介

介信吳教授 Prof. Chieh-Hsi Wu
Cardiovascular and Cancer Pharmacology
Pathological investigations and pharmacological interventions in restenosis and
cancer (angiogenesis and chemotherapy resistance)
Research TopicsResearch Topics
Representative Publications
1.Chung YL, Pan CH, Wang CCN, Hsu KC, Sheu MJ, Chen HF*, Wu CH*. J Nat Prod.
2016, 79:1635-1644.
2.Wu CH, Pan CH, Lee CK, Sheu MJ, Liu FC, Wang GJ, Wu CH*. J Funct Foods. 2016,
24:173-182.
3.Pan CH, Lin WH, Chien YC, Liu FC, Sheu MJ, Kuo YH*; Wu CH*. Toxicol Appl
Pharmacol. 2015, 282, 215-226.
4.Sheu MJ, Lin HY, Yang YH, Chou CJ, Chien YC, Wu TS, Wu CH*. Mol Nutr Food Res.
2013, 57, 1586-1597.
a. Pathological mechanisms involved in restenosis progression
b. Evaluations of bioactive compounds for applying in treatment of
restenosis, hyperlipidaemia, or cancer (angiogenesis and
chemotherapy resistance)
c. Development of drug-eluted stents
Differential expression proteins in early stages of
angioplasty- induced neointimal hyperplasia
Major research fields in our laboratory are included: (1) Exploration of pivotal
molecules involved in restenosis development by genomic and proteomic analyzes,
which help to identify the potential therapeutic targeting molecules or disease-
specific biomarkers for clinical diagnosis. (2) Evaluation of pharmacological
activities and mechanisms of natural herb-sourced bioactive compounds in
preventions of restenosis or hyperlipidaemia. (3) Developments of anti-angiogenic
agents with multiple anti-cancer mechanisms and candidate compounds against
chemotherapy resistance, which can help to improve the issues on side effects and
drug resistance of first-line chemotherapy drugs.
Major research fields in our laboratory are included: (1) Exploration of pivotal
molecules involved in restenosis development by genomic and proteomic analyzes,
which help to identify the potential therapeutic targeting molecules or disease-
specific biomarkers for clinical diagnosis. (2) Evaluation of pharmacological
activities and mechanisms of natural herb-sourced bioactive compounds in
preventions of restenosis or hyperlipidaemia. (3) Developments of anti-angiogenic
agents with multiple anti-cancer mechanisms and candidate compounds against
chemotherapy resistance, which can help to improve the issues on side effects and
drug resistance of first-line chemotherapy drugs.
Anti-angiogenic and anti-tumor evaluations of the
bioactive candidate (K20E)
Antiobesity and antihyperlipidaemic effects of Yan-
Sheng-Yin (YSY), a Chinese natural dietary supplement

劉景平教授 Prof. Jing-Ping Liou
Medicinal and Organic Chemistry
Design and synthesis of novel small molecular compounds bearing biological functions.
a. Discovery and Development of small molecules towards IND
b. Structure optimization through rational drug design
c. Total Synthesis of natural products and its intelligent modification
1.Liu, Y. M.; Nepali, K.; Liou, J. P.* Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. J. Med. Chem.
2017, 60, 527-553.
2.Lee, H. Y.; Kumar, S.; Lin, T. C.; Liou, J. P.* Total Synthesis of Denbinobin. J. Nat. Prod. 2016, 79, 1170-3.
3.Lai, M. J.; Lee, H. Y.; Chuang, H. Y.; Chang, L. H.; Tsai, A. C.; Chen, M. C.; Huang, H. L.; Wu, Y. W.; Teng, C. M.; Pan, S. L.; Liu, Y. M.;
Mehndiratta, S.; Liou, J. P.* N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of
Transcription 3 (STAT3) Signaling. J. Med. Chem. 2015, 58, 6549-58.
4.Lee, H. Y.; Tsai, A. C.; Chen, M. C.; Shen, P. J.; Cheng, Y. C.; Kuo, C. C.; Pan, S. L.; Liu, Y. M.; Liu, J. F.; Yeh, T. K.; Wang, J. C.; Chang, C. Y.;
Chang, J. Y.*; Liou, J. P.* Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit
antitumor activity in colorectal cancer HCT116 cells. J. Med. Chem. 2014, 57, 4009-22.
5.Lee, H. Y.; Pan S. L;Su, M. C., Liu, Y. M.; Kuo, C. C.; Chang, Y. T.; Wu, J. S.; Nien, C. Y.; Mehndiratta, S.; Chang, C. Y; Wu, S. Yi.;Lai, M. J.;
Chang, J. Y.*; Liou, J. P.* Furanylazaindoles: potent anticancer agents in vitro and in vivo. J. Med. Chem. 2013, 56, 8008-8018.
6.Lai, M. J.; Huang, H. L.; Pan, S. L.; Liu, Y. M,; Peng, C. Y.; Lee, H. Y.; Yeh, T. K.; Huang, P. H.; Teng, C. M.; Chen, C. S.; Chuang, H. Y.; Liou,
J. P.* Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors
with antitumor activity in vivo. J. Med. Chem. 2012, 55, 3777-3791.
Research in our laboratory is focused on the design and synthesis of small
molecular compounds as anticancer. We have experience for handling all
preclinical studies toward IND, including CMC, DMPK, GLP toxicology and safety
pharmacology. Dr. Liou’s lab uses a knowledge-based drug design approach to
create new and patentable small molecular compounds bearing biological
functions. Two such compounds passed US IND and are entering the human
clinical trials phase.
Research in our laboratory is focused on the design and synthesis of small
molecular compounds as anticancer. We have experience for handling all
preclinical studies toward IND, including CMC, DMPK, GLP toxicology and safety
pharmacology. Dr. Liou’s lab uses a knowledge-based drug design approach to
create new and patentable small molecular compounds bearing biological
functions. Two such compounds passed US IND and are entering the human
clinical trials phase.

許秀蘊教授 Prof. Shiow-Yunn Sheu
Pharmaceutical Analysis and Bioactive Natural Products
Molecular Pharmacology of TCM on Mice Bone Formation and Neuron Protection
a. Oxidized hyaluronic acid hydrogel for cartilage tissue engineering
b. Stimulatory effects of TCM on mice bone formation
c. Protective effects of TCM on mice astrocytes
1. Sheu SY, Chen WS, Sun JS, Lin FH, Wu T. Biological characterization of oxidized
hyaluronic acid/resveratrol hydrogel for cartilage tissue engineering.
J Biomed Mater Res Part A. 2013, (101A):3457-3466.
2. Sheu SY, Ho SR, Sun JS, Chen CY and Ke CJ Arthropod steroid hormone (20-
Hydroxyecdysone) suppresses IL-1β- induced catabolic gene expression in
cartilage. BMC Complementary and Alternative Medicine 2015, 15:1-8.
3. Sheu SY, Hong YW, Sun JS, Liu MH, Chen CY and Ke CJ. Radix Scrophulariae
extracts (harpagoside) suppresses hypoxia-induced microglial activation and
neurotoxicity. BMC Complementary and Alternative Medicine 2015, 15:324-332.
Schematic of the synthesis of the cross-link hyaluronic
acid containing resveratrol.
We have developed a hydrogel composed of oxidized hyaluronic acid and resveratrol
and incorporated it with cartilage cells to reverse chondrocyte degeneration.
One of the natural products, puerarin is a bone anabolic agent that exerts its
osteogenic effects through the induction of BMP-2 and NO synthesis, subsequently
regulating Cbfa1/Runx2, OPG, and RANKL gene expression. This effect may contribute
to its induction of osteoblast proliferation and differentiation, resulting in bone
formation.
It was supported a possible role for astrocytes in the mediation of neuron protection by
coumestrol. An indirect extracellular signal-regulated kinase/c-Jun N-terminal kinase
signaling pathway to down regulate the expression of interleukin 1, interleukin 6, and
the tumor necrosis factor-alpha cytotoxic effect may act in concert with the proposed
direct ER-beta biosynthesis pathway to achieve a widespread, global protection of ER-
beta positive neurons.
We have developed a hydrogel composed of oxidized hyaluronic acid and resveratrol
and incorporated it with cartilage cells to reverse chondrocyte degeneration.
One of the natural products, puerarin is a bone anabolic agent that exerts its
osteogenic effects through the induction of BMP-2 and NO synthesis, subsequently
regulating Cbfa1/Runx2, OPG, and RANKL gene expression. This effect may contribute
to its induction of osteoblast proliferation and differentiation, resulting in bone
formation.
It was supported a possible role for astrocytes in the mediation of neuron protection by
coumestrol. An indirect extracellular signal-regulated kinase/c-Jun N-terminal kinase
signaling pathway to down regulate the expression of interleukin 1, interleukin 6, and
the tumor necrosis factor-alpha cytotoxic effect may act in concert with the proposed
direct ER-beta biosynthesis pathway to achieve a widespread, global protection of ER-
beta positive neurons.
FTIR spectra of (A) HA, (B) Oxi-HA, (C) Res, (D) HA-Res.

李仁愛教授 Prof. Jen-Ai Lee
Bio-Analytical Chemistry
Pharmaceutical Analysis

何秀娥教授 Prof. Hsiu-O Ho
Pharmaceutical Analysis, Biomaterials
Development of drug delivery systems
a. Pharmaceutical Analysis
b. Development of biomaterials in drug delivery system
1. Jhan, H.J.; Liu, J.J.; Chen, Y.C.; Liu, D.Z.; Sheu M.T.* and Hon H.O*, Nanomedicine
– UK. 2014, 10(8) 1263-1274.
2. Sheu, M.T.; Jhan, H.J.; Su, C.U.; Chen, L.J.; Chang, C.E.; Liu, D.Z.; and Ho, H.O*,
Colloids and Surfaces B: Biointerfaces, 2016, 143, 260-270.
3. Jhan, H.J.; Ho, H.O; Sheu, M.T.; Shen, S.C.; Ho, Y.S.; Liu, J.J, Patent No. US
9,364,545 B2, Jun. 14, 2016.
Research in our laboratory is focused on the development of drug delivery
system with hyaluronic acid (HA). A thermosensitive injectable hydrogel
composed of nanocomplexes of doxorubicin and hyaluronic acid (HA) for the
local treatment of cancer diseases was developed and characterized. The
DH700KMF-15 hydrogel resulted in efficient growth inhibition of C26 colon
cancer cells and it selectively targeted the lymphatic system by the specific
affinity of HA to the lymphatic system in vivo.
Besides combination therapy is a potential drug delivery system for treating
tumors that might develop drug resistance. Doxorubicin (DOX) thermosensitive
hydrogels (TSHs) incorporated with docetaxel (DOC)-loaded mixed micelles were
developed to co-deliver these two drugs through a TSH system. DH700kMF-
13.5/M-DocLF is a potential dual drug delivery system, which can enhance the
efficacy of cancer chemotherapy with minimal side effects and reduced
chemoresistance.
Research in our laboratory is focused on the development of drug delivery
system with hyaluronic acid (HA). A thermosensitive injectable hydrogel
composed of nanocomplexes of doxorubicin and hyaluronic acid (HA) for the
local treatment of cancer diseases was developed and characterized. The
DH700KMF-15 hydrogel resulted in efficient growth inhibition of C26 colon
cancer cells and it selectively targeted the lymphatic system by the specific
affinity of HA to the lymphatic system in vivo.
Besides combination therapy is a potential drug delivery system for treating
tumors that might develop drug resistance. Doxorubicin (DOX) thermosensitive
hydrogels (TSHs) incorporated with docetaxel (DOC)-loaded mixed micelles were
developed to co-deliver these two drugs through a TSH system. DH700kMF-
13.5/M-DocLF is a potential dual drug delivery system, which can enhance the
efficacy of cancer chemotherapy with minimal side effects and reduced
chemoresistance.
Doxorubicin accumulation in lymph nodes.
Dox concentrations were measured at 5, 12, 24
and 48 h after a subcutaneous injection.
Tissue distributions of doxorubicin and docetaxel 72 h after SC and IT
administration of DH700KMF-15 or F-13.5/M-DocLF and DH700KMF-
13.5/M-DocLF into normal (A1 and B1) and CT-26 tumor-bearing
Balb/c mice (A2 and B2).

李慶國教授 Prof. Ching-Kuo
LeePlant metabolism and Development of cosmetic ingredients.
Representative Publications (2011-now, 3-4 papers)
a. Discovery and Development of new cosmetic ingredients
b. Plant Metabolism and Medicinal Phyto-compounds
c. Application of Hyphenated Techniques in Drug Development
1. Wang, K. C.; Cheng M. C;Hsieh, C. L., Hsu, J. F.; Wu, J. D.; Lee, C. K.* Forensic
Science International. 2013, 224, 84-89.
2.Cheng, K. T.; Wang M. Y. S.;Chou, H. C., Chang, C. C.; Lee, C. K.; Juan, S. H.
Phytomedicine. 2015, 22, 641-647.
3.Lee, T. H.; Hsu, C. C.; Hsiao, G.; Fang, J. U.; Liu, W. M.; Lee, C. K. Planta Med 2016,
82, 698–704.
4. Wu, C. H.; Pan, C. H.; Lee C. K.; She, M. J.; Liu, F. C.; Wang , G. J.; Wu, C. H.
Journal of Functional Foods 2016, 24, 173–182.
The development strategy of Natural product.
Beauty of nature
Research in our laboratory is focused on Development of new
cosmetic ingredients (Whitening, Anti-Aging); understand the
changes in plant metabolites in different environments; investigate
the effect of plant secondary metabolites and rapid analysis of life
body with MS (LC-MS/MS).
Research in our laboratory is focused on Development of new
cosmetic ingredients (Whitening, Anti-Aging); understand the
changes in plant metabolites in different environments; investigate
the effect of plant secondary metabolites and rapid analysis of life
body with MS (LC-MS/MS).

1. Lin, S. J.; Su, T. C.; Chu, C. N.; Chang, Y. C.; Yang, L. M.; Kuo, Y. C.; Huang, T. J.
J. Nat. Prod. 2016, 79, 3057−3064.
2. Huang, T. J.; Yang, C. L.; Kuo, Y. C.; Chang, Y. C.; Yang, L. M.; Chou, B. H.; Lin, S. J.*
Bioorg. Med. Chem. 2015, 23, 720−728.
3. Huang, T. J.; Chou, B. H.; Lin, C. W.; Weng, J. H.; Chou, C. H.; Yang, L. M.; Lin, S. J.*
Phytochemistry 2014, 99, 107−114.
4. Chang, S. F.; Yang, L. M.; Huang, T. J.; Chen, J. Y.; Sheu, J. Y.; Liu, P. C.; Lin, S. J.*
Phytochemistry 2013, 95, 268−276.
Research in our group is involved the isolation and structure elucidation of novel organic
metabolites produced by microbial transformation of naturally occurring substances that
possess interesting structures and useful biological activities. The structures of the new
metabolites are elucidated primarily by spectroscopic analysis. 1D and 2D NMR experiments
play a pivotal role in the structure elucidation. Our current efforts also focus on the preparation
of chiral products by microbial transformation. These chiral products are then employed in the
syntheses of compounds for the discovery and development of new biological activities. We are
also actively collaborating with other researchers to identify and develop natural and synthetic
small-molecule based candidates for anti-virus, anti-inflammation and anti-tumor, and
elucidate their corresponding mechanisms of action. The experimental approach taken by our
laboratory is multidisciplinary, relying on the tools of synthetic chemistry, medicinal chemistry,
enzymology, biochemical pharmacology, X-ray crystallography, and spectroscopy to address
our goal.
Research in our group is involved the isolation and structure elucidation of novel organic
metabolites produced by microbial transformation of naturally occurring substances that
possess interesting structures and useful biological activities. The structures of the new
metabolites are elucidated primarily by spectroscopic analysis. 1D and 2D NMR experiments
play a pivotal role in the structure elucidation. Our current efforts also focus on the preparation
of chiral products by microbial transformation. These chiral products are then employed in the
syntheses of compounds for the discovery and development of new biological activities. We are
also actively collaborating with other researchers to identify and develop natural and synthetic
small-molecule based candidates for anti-virus, anti-inflammation and anti-tumor, and
elucidate their corresponding mechanisms of action. The experimental approach taken by our
laboratory is multidisciplinary, relying on the tools of synthetic chemistry, medicinal chemistry,
enzymology, biochemical pharmacology, X-ray crystallography, and spectroscopy to address
our goal.
1. The search for bioactive substances (isolation, structure elucidation, synthesis)
2. Synthesis of natural product-like compounds to develop new bioactive substances
3. Microbial transformations of naturally occurring substances
ORTEP drawing of the X-ray structures of isomeric isosteviol lactone
COOH
O
O
COOH
O
O
Effects of compound 6 on NF-κB p65/p50, Erk 1/2,
and p38 MAPK protein expressions in Huh7 cells
that expressed the HBV genome
林淑娟教授 Prof. Shwu-Jiuan Lin
Medicinal chemistry
Microbial transformation

許明照教授 Prof. Ming-Thau Sheu
Pharmaceutics and Pharmaceutical Science
Drug dosage forms and drug delivery systems
a. Oral controlled release dosage forms
b. Lecithin-stabilized nanocarrier systems
c. Albumin nanoparticles
In Sheu’s lab, phamaceutical nanotechnology includes self-assembly mixed polymeric
micelles (SAMPM), lecithin-stabilized nanocarrier systems (LSNS), protein-based
(Albumin) nanoparticles, and targeting of those pegylated nanocarriers by
bispecific/trispecific antibody have been my research’s interests. A new SAMPM system
composed of amphiphilic polymers and lipids and simply prepared by a thin-film method
demonstrates its potential benefit as a carrier for delivering two poorly water-soluble
drugs. LSNS are a pharmaceutically/nutraceutically drug nanocarrier comprising a lipid
shell enclosing a micellar core composed of an amphiphilic polymer with/without
phospholipid or emulsifier, wherein a pharmaceutically or nutraceutically active
ingredient is disposed. LSNS developed for carrying docetaxel has been conducted to
demonstrate in vitro and in vivo characteristics. Nanoparticle albumin-bound (Nab)-
technology is a new technology for anti-cancer drug delivery system which have been
developed in my lab.
In Sheu’s lab, phamaceutical nanotechnology includes self-assembly mixed polymeric
micelles (SAMPM), lecithin-stabilized nanocarrier systems (LSNS), protein-based
(Albumin) nanoparticles, and targeting of those pegylated nanocarriers by
bispecific/trispecific antibody have been my research’s interests. A new SAMPM system
composed of amphiphilic polymers and lipids and simply prepared by a thin-film method
demonstrates its potential benefit as a carrier for delivering two poorly water-soluble
drugs. LSNS are a pharmaceutically/nutraceutically drug nanocarrier comprising a lipid
shell enclosing a micellar core composed of an amphiphilic polymer with/without
phospholipid or emulsifier, wherein a pharmaceutically or nutraceutically active
ingredient is disposed. LSNS developed for carrying docetaxel has been conducted to
demonstrate in vitro and in vivo characteristics. Nanoparticle albumin-bound (Nab)-
technology is a new technology for anti-cancer drug delivery system which have been
developed in my lab.
1. Jhan HJ, Liu JJ, Chen YC, Liu DZ, Sheu MT, Ho HO. Novel injectable thermosensitive
hydrogels for delivering Hyaluronic acid-doxorubucin nanocomplexes to locally treat
tumors. Nanomedicine-UK. 2015.
2. Ying-Chen Chen, Ray-Neng Chen, Hua-Jing Jhan, Der-Zen Liu, Hsiu-O Ho, Yong Mao,
Joachim Kohn, and Ming-Thau Sheu, (2015). Development and characterization of
acellular extracellular matrix scaffolds from porcine menisci for use in cartilage
tissue engineering. Tissue Eng. 21(9):971-986.
3. Ying-Chen Chen, Chia-Yu Su, Hua-Jun Jhan, Hsiu-O Ho, Ming-Thau Sheu (2015).
Physical characterization and in vivo pharmacokinetic study of self-assembling
amphotericin B-loaded lecithin-based mixed polymeric micelles. Int. J. Nanomed.
10:7265–7274.

廖嘉鴻教授 Prof. Jiahorng Liaw
Pharmaceutics
Drug and Gene Delivery with Mechanism Investigation
1. WH Hsieh, SF Chang, HM
Chen, JH Chen, J Liaw (2012).
Oral Gene Delivery with cyclo-
(d-Trp-Tyr) Peptide
Nanotubes. Mol Pharmaceut,
9, 1231-1249
2. YC Tong, TY Yu, SF Chang, J
Liaw (2012). Nano-polymeric
micelle effect on the
transdermal permeability, the
bioavailability and gene
expression of plasmid. Mol
Pharmaceut, 9:111-120.
3. YC Tong, SF Chang, WWY Kao,
CY Liu, J Liaw (2010).
Polymeric micelle gene
delivery of bcl-xL via eye drop
reduced corneal apoptosis
following epithelial
debridement. J Control Rel,
147:76-83.

Blue light-induced Retinopathy
鄭幼文教授 Prof. Yu-Wen
Cheng
Pharmacology and ToxicologyDrugs Development and Toxicity Test
a. Drugs Development of Anti-mucositis and Anticancer.
b. Drugs Development of Retinopathy and Age-Relative Macular
Degeneration Diseases.
c. Toxicity test for food, drugs and cosmetics.
Research in our laboratory is focused on the development of the drugs as
the treatment of anticancer, anti-mucositis, anti-inflammatory and the
treatment for retinopathy and AMD. One of our newly developped compound
was granted from MOE showed significant mucositis inhibition on
chemotherapy induced whole body animal intestinal mucositis on C57BL/B6
mice. We also developed retinopathy animal models as platform for screening
light, drugs, toxins, and environmental agents induced eye diseases,
especially on dry-form AMD.
Research in our laboratory is focused on the development of the drugs as
the treatment of anticancer, anti-mucositis, anti-inflammatory and the
treatment for retinopathy and AMD. One of our newly developped compound
was granted from MOE showed significant mucositis inhibition on
chemotherapy induced whole body animal intestinal mucositis on C57BL/B6
mice. We also developed retinopathy animal models as platform for screening
light, drugs, toxins, and environmental agents induced eye diseases,
especially on dry-form AMD.
1. Lin CH, Wu MR, Li CH, Cheng HW, Huang SH, Tasi CH; Ho JD, Kang JJ; Hsiao
G; Cheng YW* (2017) Periodic exposure to smartphone-mimic low-
luminance blue light induces retina damage through Bcl-2/BAX-dependent
apoptosis. Toxicological Science.(Accepted).
2. Liao PL, Lin CH, HoJD, LiCH, Tsai CH, Chiou GCY, KangJJ, Cheng YW*(2017)
Anti-inflammatory properties of shikonin contribute to improved early-
stage diabetic retinopathy. Scientific Report (Accepted).
3. Lin FL, Lin CH, Ho JD, Yen JL, Chang HM, George C.Y.Chiou; Cheng YW*,
Hsiao G* (2017).The natural retinoprotectant chrysophanol attenuated
photoreceptor cell apoptosis in an N-methyl-N-nitrosourea-induced
mouse model of retinal degeneration. Scientific Report.(Accepted)

Our laboratory studied on the pharmacokinetics of drugs/TCMs and their
related hyperglycemic activity. We are particularly interested in FA, AFE, EMF and
ST derivatives, the naturally occurring substances extracted from TCMs and some
of them are consumed as dietary supplement. The HPLC analytical method usually
have been developed to measure the plasma levels of cpds. The pharmacokinetic
parameters would be then calculated and reveal the disposition of compounds in
the body/animal. By the calcium imaging technique, we screen the herb
extracts/its derivatives with [Ca2+
]I changes in vitro to investigate how herb
extracts regulate calcium signals and how this related with insulin release in
pancreatic β-cells. The glucose uptake in skeleton muscle/adipocytes and induced
hyperglycemic animal experiment also utilized to understand the hypoglycermic
activity of these herb cpds. Our findings, not only in vitro but also in vivo,
that these natural occurring products may be beneficial for the concomitant in
disease treatment by their regulation of hypoglycemic activity.
Our laboratory studied on the pharmacokinetics of drugs/TCMs and their
related hyperglycemic activity. We are particularly interested in FA, AFE, EMF and
ST derivatives, the naturally occurring substances extracted from TCMs and some
of them are consumed as dietary supplement. The HPLC analytical method usually
have been developed to measure the plasma levels of cpds. The pharmacokinetic
parameters would be then calculated and reveal the disposition of compounds in
the body/animal. By the calcium imaging technique, we screen the herb
extracts/its derivatives with [Ca2+
]I changes in vitro to investigate how herb
extracts regulate calcium signals and how this related with insulin release in
pancreatic β-cells. The glucose uptake in skeleton muscle/adipocytes and induced
hyperglycemic animal experiment also utilized to understand the hypoglycermic
activity of these herb cpds. Our findings, not only in vitro but also in vivo,
that these natural occurring products may be beneficial for the concomitant in
disease treatment by their regulation of hypoglycemic activity.
何意副教授 Associate Prof. Yih Ho
Pharmacokinetics and Pharmaceutics
The Pharmacokinetics of natural occurring compounds
Representative Publications (2010-now, 3-4 papers)
a. The pharmacokinetics of drugs/TCMs and their interaction
b. Potential natural products having hypoglycemic activity with insulin
release/glucose uptake properties.
c. Pharmacophore modeling to design the potential enzyme
Inhibitors (cooperated with NTUT lab)
Zheng-Li Zhou, Hsuan-Liang Liu, Josephine W. Wu, Cheng-Wen Tsao, Wei-Hsi Chen,
Kung-Tien Liu and Yih Ho, “ Computer-aided discovery of potential inhibitors for
transthyretin-related amyloidosis”, Journal of the Chinese Chemical Society, 61(2),
263–273(2014)
Yu-Syuan Lin, Yih Ho, Chaur-Jong Hu, Wan-Wen Su, Kuang-Yang Hsu, Winston W.
Shen, Chuang Chin Chiueh and Rey-Yue Yuan, JECM, 5, 77-80 (2013).
HPLC chromatogram
of IRM
The plasma glucose level and increment AUC changes
following administration of AFE analysis
[Ca2+
]I change of EMF The best SB_Hypo1 and ERB-041

建吳德副教授 Associate Prof. Jender Wu
Customized synthesis of small molecules possessing biological activities and particular
applications
a. Synthesis of active metabolites.
b. Design and synthesis of congeners or derivatives of active natural
products.
1. Wang KC, Cheng MC, Hsieh CL, Hsu JF, Wu JD*, Lee CK*. Forensic Sci Int. 2013,
224, 84-89.
2.Chen PY, Wu JD, Tang KY, Yu CC, Kuo YH, Zhong WB, Lee CK. Molecules. 2013, 18,
7600-7608.
3. Wu JD, Chien CC, Yang LY, Huang GC, Cheng MC, Lin CT, Shen SC, Chen YC. Chem
Biol Interact. 2011, 193, 3-11
In our laboratory, we focus on several research fields. The metabolites of the
abused drug, e.g. nimetazepam and nitrazepam, were synthesized as the
standard for medical and forensic uses.
We also synthesized different naphthoquinone derivatives and evaluated
their cytotoxicity and biological mechanisms. For example, 2-methyl-1,4-
naphthoquinone (vitamin K3), which belongs to the vitamin K family, is a
synthetic drug for the coagulation disorder. Vitamin K3 and its oxidized form,
menadione-2,3-epoxide, were toxic against glioma cells. They are able to induce
apoptosis in human glioma cells by activation of ROS-dependent ERK and JNK
protein phosphorylation. Further development of naphthoquinone-based
anticancer studies as well as other applications other than biological purposes
are currently undergoing.
In our laboratory, we focus on several research fields. The metabolites of the
abused drug, e.g. nimetazepam and nitrazepam, were synthesized as the
standard for medical and forensic uses.
We also synthesized different naphthoquinone derivatives and evaluated
their cytotoxicity and biological mechanisms. For example, 2-methyl-1,4-
naphthoquinone (vitamin K3), which belongs to the vitamin K family, is a
synthetic drug for the coagulation disorder. Vitamin K3 and its oxidized form,
menadione-2,3-epoxide, were toxic against glioma cells. They are able to induce
apoptosis in human glioma cells by activation of ROS-dependent ERK and JNK
protein phosphorylation. Further development of naphthoquinone-based
anticancer studies as well as other applications other than biological purposes
are currently undergoing.

林美香副教授 Associate Prof. Mei-Hsiang Lin
Design and synthesis of novel small molecular compounds bearing biological functions.
a. Discovery and Development of small molecules
b. Structure optimization through rational drug design
c. Isolation and modification of natural products
1. Chiang, L. L.; Tseng, I. J.; Lin, P. Y.; Sheu, S. Y.; Lin, C. T.; Hsieh, Y. H.; Lin, Y. J.;
Chen, H. I.; and Lin, M. H.*
Molecules 2016, 12, 100.
2. Tseng, I. J.; Lin, P. Y.; Sheu, S. Y.; Tung, W. N.; Lin, C. T.; and Lin, M. H.*
J. Chin.
Chem. Soc. 2015, 62, 59-63.
3. Lin, M. H.; Cheng, C. H.; Chen, K. C.; Lee, W. T.; Wang, Y. F.; Xiao, C. Q.; and Lin, C.
W.* Chem-Biol. Interact. 2014, 218, 42-49.
4. Lin, M. H.; Liu, H. K.; Huang, W. J.; Huang, C. C.; Wu, T. H.; and Hsu, F. L.*
J. Agr.
Food Chem. 2011, 59, 7743-7751.
Research in our laboratory is focused on the design and synthesis of small molecular compounds as anti-diabetes, anti-
inflammatory agents, and Anti-Cataract Agents. The anti-inflammatory activities of these derivatives were evaluated by means of
inhibiting NO production in LPS-induced RAW 264.7 cells. Five derivatives exhibited low micromolar levels of anti-inflammatory
activities, and these derivatives also protected DNA against hydroxyl radical attack. Coumarin derivative 8 was the most potent
derivative among those tested herein against NO production in LPS-induced RAW 264.7 cells with an IC50 value of 7.6 µM, and it
effectively reduced the hydroxyl radical production by 50% at 100 µM in the electron spin resonance study. Coumarin 7, 6-benzoyl-
5,6-dihydroxy-4-phenyl-chromen-2-one, was found to have the most potent activity in protecting porcine γ-crystallin against UVC
insults. Results of fluorescence assays indicated that compound 7 was capable of decreasing the loss of intensity while lens crystallins
and DNA PUC19 were irradiated with UVC. Presence of compound 7 decreased hydroxyl radical levels determined by probe 1b and the
free iron concentrations determined by Ferrozine reagent. The chelation assay showed that compound 7 was chelated to metal via 6-
CO and 5-OH on the benzopyrone ring. The observed protective effects of compound 7 towards crystallins from insults of UVC and
freeradicals may be due to its iron-chelating activity and its peak absorption at 254 nm.
Research in our laboratory is focused on the design and synthesis of small molecular compounds as anti-diabetes, anti-
inflammatory agents, and Anti-Cataract Agents. The anti-inflammatory activities of these derivatives were evaluated by means of
inhibiting NO production in LPS-induced RAW 264.7 cells. Five derivatives exhibited low micromolar levels of anti-inflammatory
activities, and these derivatives also protected DNA against hydroxyl radical attack. Coumarin derivative 8 was the most potent
derivative among those tested herein against NO production in LPS-induced RAW 264.7 cells with an IC50 value of 7.6 µM, and it
effectively reduced the hydroxyl radical production by 50% at 100 µM in the electron spin resonance study. Coumarin 7, 6-benzoyl-
5,6-dihydroxy-4-phenyl-chromen-2-one, was found to have the most potent activity in protecting porcine γ-crystallin against UVC
insults. Results of fluorescence assays indicated that compound 7 was capable of decreasing the loss of intensity while lens crystallins
and DNA PUC19 were irradiated with UVC. Presence of compound 7 decreased hydroxyl radical levels determined by probe 1b and the
free iron concentrations determined by Ferrozine reagent. The chelation assay showed that compound 7 was chelated to metal via 6-
CO and 5-OH on the benzopyrone ring. The observed protective effects of compound 7 towards crystallins from insults of UVC and
freeradicals may be due to its iron-chelating activity and its peak absorption at 254 nm.

梁文俐副教授 Associate Prof. Wen-Li Liang
Chinese herbal medicine and Natural plant research
a. Antioxidant Activity
b. Antibacterial Activity
c. Quality control of Chinese herbal medicines
d. Chinese herbal medicine processing
1. Yun-Yang Lee, Hsieh-Yu Li, Shih-Jiuan Chiu, Wen-Li Liang, Pi-Li Yeh and Ying-Ling Liu
(2015), Redox reaction mediated direct synthesis of hierarchical flower-like CuO
spheres anchored on electrospun poly(vinylidene difluoride) fiber surfaces at low
temperatures, RSC Adv., 5, 100228–100234
2. Lee Tzong-Huei, Tsai Yow-Fu, Huang Tzu-Tien, Chen Pi-Yu, Liang Wen-Li*, Lee
Ching-Kuo* (2012), Heptadecanols from the leaves of Persea americana var.
Americana, Food Chemistry, 132, 921–924.
3. Guei-Jane Wang, Wen-Li Liang, Yu-Ming Ju, Wen-Bin Yang, Ya-Wen Chang, and
Tzong-Huei Lee (2012). Inhibitory Effects of Terpenoids from the Fermented Broth
of the Ascomycete Stilbohypoxylon elaeicola YMJ173 on Nitric Oxide Production in
RAW264.7 macrophages, Chemistry & Biodiversity(9)131-138

邱士娟副教授 Associate Prof. Shih-Jiuan Chiu
School of Pharmacy, Taipei Medical University
Pharmaceutics/Drug and/or Gene Delivery, Dosage Form Design
a. Delivery of gene/siRNA/antisense agents by nanoparticles or liposomes
b. Targeted drug/gene/antisense delivery systems
c. Nanoparticle design and synthesis
d. Development of novel biomaterials for drug/gene/antisense delivery
1. Chiu SJ, Lin CY, Chou HC, Hu TM (2016). Silica ouzo effect: Amphiphilic drugs facilitate nanoprecipitation of polycondensed
mercaptosilanes, Langmuir (32):211-220
2. Wang MR, Chiu SJ, Chou HC, Hu TM (2015).An efficient S-NO-polysilsesquioxane nano-platform for the co-delivery of nitric oxide
and an anticancer drug. Chemical Communications (51):15649-15652.
3. Chou HC, Chiu SJ, Hu TM (2015). LbL assembly of albumin on nitric oxide-releasing silica nanoparticles using Suramin, a polyanion
drug, as an interlayer linker. Biomacromolecules (16):2288-2295.
4. Chou HC, Chiu SJ, Liu YL, and Hu TM (2014). Direct Formation of S-Nitroso Silica Nanoparticles from a Single Silica Source. Langmuir
(30): 812-822
5. Chiu SJ, Wang SY, Chou HC, Liu YL, Hu TM (2014). Versatile synthesis of thiol- and amine-bifunctionalized silica nanoparticles based
on the ouzo effect. Langmuir (30):7676-7686
Research in our laboratory is focused on delivery of gene/antisense to tumors and development of targeted
drug delivery systems by nanoparticles or liposomes. These nanoparticles serve as carriers for various
therapeutic agents, including small molecules like chemotherapeutic agents and large molecules like protein,
peptides, and nucleic acids such as plasmid DNA, antisense oligonucleotides, siRNA, and miRNA to enhance
their therapeutic efficacy in patients. Our effort is mainly focused on optimizing nanoparticle formulations
based on rational design and directed at clinical applications.
Research in our laboratory is focused on delivery of gene/antisense to tumors and development of targeted
drug delivery systems by nanoparticles or liposomes. These nanoparticles serve as carriers for various
therapeutic agents, including small molecules like chemotherapeutic agents and large molecules like protein,
peptides, and nucleic acids such as plasmid DNA, antisense oligonucleotides, siRNA, and miRNA to enhance
their therapeutic efficacy in patients. Our effort is mainly focused on optimizing nanoparticle formulations
based on rational design and directed at clinical applications.

李學耘助理教授 Assistant Prof. Hsueh-Yun Lee
a. 1.Drug design and development
b. 2.Lead optimization
c. 3.Organic synthesis
d. 4.Total synthesis of natural products
We are interested in designing and synthesizing novel molecules
with promising biological activity. Recently, we have developed
some antitubulin agents and HDAC inhibitors, which exhibited
remarkable anticancer activity. In addition, we also keep
synthesizing small molecules with different mechanism of action.
We are interested in designing and synthesizing novel molecules
with promising biological activity. Recently, we have developed
some antitubulin agents and HDAC inhibitors, which exhibited
remarkable anticancer activity. In addition, we also keep
synthesizing small molecules with different mechanism of action.
1. Nepali, K.; Kumar, S.; Huang, H. L.; Kuo, F. C.; Lee, C. H.; Kuo, C. C.; Yeh, T. K.; Li, Y. H.; Chang, J. Y.;
Liou, J. P.; Lee, H. Y.* Org. Biomol. Chem. 2015, 14, 716-723.
2. Lee, H. Y.; Wang, L. T.; Li, Y. H.; Pan, S. L.; Chen, Y. L.; Teng, C. M.; Liou, J. P.* Org. Biomol. Chem. 2014,
12, 8966-8976.
3. Lee, H. Y.; Tsai, A. C.; Chen, M. C.; Shen, P. J.; Cheng, Y. C.; Kuo, C. C.; Pan, S. L.; Liu, Y. M.; Liu, J. F.;
Yeh, T. K.; Wang, J. C.; Chang, C. Y.; Chang, J. Y.; Liou, J. P.* J. Med. Chem. 2014, 57, 4009–4022.

Blue light-induced Retinopathy
鄭慧文教授 Prof. David Hui-Wen Cheng
美國加州大學藥學博士 (University of California, USA)
台灣大學藥學士 (National Taiwan University, BS)
Pharmaceutical Management, Regulatory Affairs
a. Pharmaceutical Marketing.
b. Pharmaceutical Regulations.
c. Pharmaceutical R&D Management.
1. Lin CH, Wu MR, Li CH, Cheng HW, Huang SH, Tasi CH; Ho JD, Kang JJ; Hsiao G;
Cheng YW (2017) Periodic exposure to smartphone-mimic low-luminance blue
light induces retina damage through Bcl-2/BAX-dependent apoptosis.
Toxicological Science.(Accepted).
2. Lin HC,Hsiao YT, Lin HL, Uang YS, Cheng HW, Wang Y and Wang LH.(2016) The use
of proton pump inhibitors decreases the risk of diabetes mellitus in patients with
upper gastrointestinal disease A population-based retrospective cohort study.
Medicine 95: 28 (1-5)
3. Lin CH; Liao PL, Hsiao G, Li CH, Huang SH, Tsai CH, Wu MR; Ho JD, Cheng HW,
Cheng YW (2015) Long-term fluorometholone topical use induces ganglion cell
damage in rats analyzed with optical coherence tomography. Toxicological
Science. 147(2):317-325.
4. Lin HC, Kachingwe BH, Lin HL, Cheng HW, Uang YS, Wang LH (2014) Effects of
Metformin Dose on Cancer Risk Reduction in Patients with Type 2 Diabetes
Mellitus: A 6-Year Follow-up Study. Pharmacopherapy.34(1):36-45.
5. Cheng HW, Lee KC, Cheah KP, Chang ML, Lin CW, Li JS, Yu WY, Liu ET, Hu CM
(2013) Polygonum viviparum L. inhibits the lipopolysaccharide-induced
inflammatory response in RAW264.7 macrophages through haem oxygenase-1
induction and activation of the Nrf2 pathway. Journal of Science and Food
Agriculture.(93):491-497.

姿樺吳教授 Prof. Tzu-Hua Wu, Ph.D.
Department of Clinical Pharmacy, Taipei Medical University
Biochemistry and Pharmacotherapeutics
Clinical Pharmacy & Therapeutics Drug Utilization Evaluations and Managements.
a. Therapeutic drug monitoring and clinical pharmacokinetics in psychiatrics and
blood disorders
b. Biochemical pharmacology of Chinese herbal medicine in cataract and infertility
c. Pharmaceutical care and managements
1. Lu MY, Lin TH, Chiang PH, Kuo PH, Wang N, Wu WH, Lin KH, Wu TH*. Deferasirox-Iron
Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia
Major. Ther Drug Monit. 2017 Jan 30. doi: 10.1097/FTD.0000000000000378.
2. Liao JH, Huang YS, Lin YC, Huang FY, Wu SH, Wu TH*. Anticataractogenesis Mechanisms of
Curcumin and a Comparison of Its Degradation Products: An in Vitro Study. J Agric Food
Chem. 2016; 64(10):2080-6.
3. Lu ML, Wu YX, Chen CH, Kuo PT, Chen YH, Lin CH, Wu TH*. Application of plasma levels of
olanzapine and n-desmethyl-olanzapine to monitor clinical efficacy in patients with
schizophrenia. PLoS One 2016;11(2):e0148539.
4. Lu MY, Wang N, Wu WH, Lai CW, Kuo PH, Chiang PH, Lin KH, Wu TH*. Simultaneous
determination of plasma deferasirox and deferasirox-Iron complex using an HPLC-UV system
and pharmacokinetics of deferasirox in patients with β-Thalassemia major: once-daily versus
twice-daily administration. Clin Ther. 2015 S0149-2918(15)00845-0.
5. Chen YC, Pan LC, Lai CW, Chien YS Wu TH*. Silymarin and protein kinase A inhibitor
modulate glucose-mediated mouse sperm motility: An in vitro study. Reprod Biol.
2015;15(3):172-7.
Therapeutic Drug Monitoring on correlation between
metabolic syndromes and levels of clinical
drug/metabolite by HPLC-ECD system in patients.
Dr. Wu’s researches focus on Therapeutic Drug Monitoring research particularly in
the field of Neuropsychiatry, Pediatrics and Biochemical nutrition to improve patients’
therapeutic outcomes. Being a director for Pharmacist Association, Dr. Wu not only
considers patients’ benefits but also put her efforts on supporting systems to
facilitate performance of pharmacists. She published more than 30 research articles
before 2016 and also serves as reviewers for several journals including in managed
care field.
Dr. Wu’s researches focus on Therapeutic Drug Monitoring research particularly in
the field of Neuropsychiatry, Pediatrics and Biochemical nutrition to improve patients’
therapeutic outcomes. Being a director for Pharmacist Association, Dr. Wu not only
considers patients’ benefits but also put her efforts on supporting systems to
facilitate performance of pharmacists. She published more than 30 research articles
before 2016 and also serves as reviewers for several journals including in managed
care field.
PLOS ONE 2013 8(5):e65719.
Proposed role for curcumin and its effective degradation
as an anti-cataract drugs. J Agric Food Chem. 2016

Dr. Yu (Nancy) Ko obtained her B.Sc. in Pharmacy from the National Taiwan University
and holds a Masters degree in Pharmacy Administration from the University of Illinois at
Chicago. She received her Ph.D. in Pharmaceutical Economics, Policy, and Outcomes
Research from the University of Arizona and was a founding member of the Singapore
chapter of the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). Dr. Ko’s research experience and publications lie in the areas of
pharmacoeconomics, psychometrics, and patient-reported outcomes. She is
collaborating with local pharmacists and other health care providers on several research
projects that aim to improve the safety and cost-effectiveness of drug use in Taiwan.
Dr. Yu (Nancy) Ko obtained her B.Sc. in Pharmacy from the National Taiwan University
and holds a Masters degree in Pharmacy Administration from the University of Illinois at
Chicago. She received her Ph.D. in Pharmaceutical Economics, Policy, and Outcomes
Research from the University of Arizona and was a founding member of the Singapore
chapter of the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR). Dr. Ko’s research experience and publications lie in the areas of
pharmacoeconomics, psychometrics, and patient-reported outcomes. She is
collaborating with local pharmacists and other health care providers on several research
projects that aim to improve the safety and cost-effectiveness of drug use in Taiwan.
戈鈺副教授 Associate Prof. Yu (Nancy) Ko, Ph.D.
Pharmaceutical Economics, Policy, and Outcomes Research
Research AreasResearch Areas
a. Pharmacoeconomics
b. Drug utilization review
c. Health service research
d. Psychometrics
e. Patient-reported outcomes (PROs)
1. Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Patient-reported health preferences of anticoagulant-related outcomes. J Thromb
Thrombolysis. 2015;40(3):268-73.
2. Ng CS, Toh MP, Ng J, Ko Y. Direct medical cost of stroke in Singapore. Int J Stroke. 2015;10 Suppl A100:75-82.
3. Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke
prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2014;28:575-85.
4. Ko Y, Gwee YS, Huang YC, Chiang J, Chan A. Costs and length of stay of drug-related hospital admissions in cancer patients. Clin
Ther. 2014;3:588-92.
5. Ko Y, Lo NN, Yeo SJ, Yang KY, Yeo W, Chong HC, Thumboo J. Comparison of the responsiveness of the SF-36, the Oxford Knee Score,
and the Knee Society Clinical Rating System in patients undergoing total knee replacement. Qual Life Res. 2013;22:2455-9.
6. Ko Y, Tan SL, Chan A, Wong YP, Yong WP, Ng RCH, Lim SW, Salim A. Prevalence of the co-prescription of clinically important
interacting drug combinations involving oral anticancer agents: a retrospective database study. Clin Ther. 2012;34:1696-704.

王莉萱副教授 Associate Prof. Li-Hsuan Wang
Clinical pharmacokinetic, Pharmacoepidemiology and Clinical Pharmacy and Therapeutics
a. Natural product and drug interaction
b. Pharmacoepidemiology and therapeutic risk management
c. Nonclinical pharmacokinetics study
d. Clinical pharmacokinetic study
1. Lin HC, Daimon M, Wang C-H, Ho Y, Uang YS, Chiang S-J, Wang L-H (2017). Allopurinol, Benzbromarone, and
Risk of Coronary Heart Disease in Gout Patients: a Population-Based Study. International Journal of
Cardiology 233: 85-90.
2. Lin HC, Hsiao YT, Lin HL, Uang YS, Cheng HW, Wang Y, Wang L-H (2016). The Use of Proton Pump Inhibitors
Decreases the Risk of Diabetes Mellitus in Patients with Upper Gastrointestinal Disease. A Population-Based
Retrospective Cohort Study. Medicine 95 (28): e4195.
3. Wang L-H, Liu CK, Chen CH, Kao LT, Lin HC, Huang CY (2016). No increased risk of coronary heart diseases for
patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. Andrology 4
(1): 128-132.
4. Huang CY, Chung SD, Kao LT, Lin HC, Wang L-H (2015). Statin use is associated with bladder pain
syndrome/interstitial cystitis: A population-based case-control study. Urologia Internationalis 95 (2): 227-
232
5. Chiang SJ, Daimon M, Wang L-H, Hung M-J, Chang N C, Lin HC (2015). Association between mitral value
prolapse and open-angle glaucoma. Heart 101: 609-615.
6. Chung S-D, Chen C-H, Hung S-H, Lin H-C, Wang L-H (2015). A Population-Based Study on the Association
between Statin Use and Sudden Sensorineural Hearing Loss. Otolaryngology-Head and Neck Surgery 152 (2):
319-325.

陳香吟副教授 Associate Prof. Shawn Hsiang-Yin Chen, M.S., Pharm.D.
Clinical Pharmacy and Medication Management
Optimization the medication use and pharmacy service in clinical practice
a.Pharmacogenomics and pharmacoepidemiology on pulmonary medicine
b. Development and evaluation of new pharmacy practice models
c. Bioinformatics and cloud-based medication record
Dr. Chen completed her clinical research and practice training at University of Iowa and
receives dual appointments from TMU and TMU-Wanfang Medical Center. She has served as
the pharmacy director, Wanfang Medical Center for 12 years, establishing complementary
models of pharmacy care. She was the funding chairperson of clinical pharmacy division,
establishing the 6 year pharmacy education program at TMU School of Pharmacy. Research in
Dr. Chen’s laboratory is focused on optimizing the medication use in clinical settings. Applying
the skills of pharmacogenomics, pharmacovigilance and bioinformatics, she published many
articles on cisplatin-induced nephrotoxicity, tuberculosis agents induced hepatic injury,
pediatric medication errors prevention, formulary management, cost containment, medication
reconciliation, pharmacy informatics, and clinical pharmacy service (IV-to-PO service,
antocoagulation, and antibiotics stewardship) for documenting the value of pharmacy service.
Dr. Chen completed her clinical research and practice training at University of Iowa and
receives dual appointments from TMU and TMU-Wanfang Medical Center. She has served as
the pharmacy director, Wanfang Medical Center for 12 years, establishing complementary
models of pharmacy care. She was the funding chairperson of clinical pharmacy division,
establishing the 6 year pharmacy education program at TMU School of Pharmacy. Research in
Dr. Chen’s laboratory is focused on optimizing the medication use in clinical settings. Applying
the skills of pharmacogenomics, pharmacovigilance and bioinformatics, she published many
articles on cisplatin-induced nephrotoxicity, tuberculosis agents induced hepatic injury,
pediatric medication errors prevention, formulary management, cost containment, medication
reconciliation, pharmacy informatics, and clinical pharmacy service (IV-to-PO service,
antocoagulation, and antibiotics stewardship) for documenting the value of pharmacy service.
1. Lee YY, Kuo LN, Chiang YC, JY Hou, Wu TY, Hsu MH, Chen HY*. Pharmacist Conducted
Medcation Reconciliation at Hospital Admission using Information Technology. International
Journal of Medical Informatics. 2013; 82: 522-7.
2. Liu HE, Bai KJ, Hsieh YC, Yu MC, Lee CN, Chang JH, Hsu HL, Lu PC, Chen HY*. Multiple
analytical approaches demonstrate a complex relationship of genetic and non-genetic factors
with cisplatin- or carboplatin-induced nephrotoxicity in lung cancer patients. BioMed
Research International. 2014; Article ID 937429, 1-9.
3. Chen CM, Kuo CN, Cheng KJ, Shen WC, Bai KJ, Wang CC, Chiang YC, Chen HY*. The Effect of
Medication Therapy Management Service Combined with a National PharmaCloud System
for Polypharmacy Patients. Computer Methods and Programs in Biomedicine, 2016; 134:109-
19.

宗軒吳助理教授 Assistant Prof. Chung-Hsuen Wu
Pharmacoepidemiology and outcomes research
a. Pharmacoepidemiology ( 藥物流行病學 ) and pharmacoeconomics ( 藥事經濟學 )
b. Medication adherence ( 服藥順從性 ) and health service research among patients with
chronic diseases
c. Pharmaceutical outcomes research using large administrative data and complex sample
survey data ( 資料庫研究 )
1. Wu CH*, Wang CC, Katz AJ, Farley JF. (2013) “National trends of psychotropic medication use among patients diagnosed with
anxiety disorders: Results from Medical Expenditure Panel Survey 2004-2009” Journal of Anxiety Disorder. 27 (2): 163-170
2. Wu CH*, Wang CC, Kennedy J. (2013) “The prevalence of herb and dietary supplement use among children and adolescents in the
United States: Results from the 2007 National Health Interview Survey” Complementary Therapies in Medicine. 21(4):358-363
3. Wu CH*, Farley JF, Gaynes BN. (2012) “The association between antidepressant dosage titration and medication adherence among
patients with depression.” Depression and Anxiety. 29 (6): 506-514
Dr. Wu’s research interests focus on medication-related health outcomes, including medication adherence, persistence, and health
resource utilization among patients with chronic diseases. With multidisciplinary training in pharmacy, health policy and
administration, and health services research, Dr. Wu has extensive experience working with large health claims data and complex
sample survey data to conduct pharmaceutical outcomes research. He is familiar with administrative claims data such as MarketScan®
Commercial Claims data, MarketScan® Multi-States Medicaid Administrative data, and Humana Medicare and Commercial Claim Data
as well as complex survey data such as the Medical Expenditure Panel Survey (MEPS), National Comorbidity Survey-Replication (NCS-R),
and National Health Interview Survey (NHIS).
Prior to his current appointment, Dr. Wu was a Human/UNC Pharmaceutical Outcomes Post-Doctoral Research Fellow in the Eshelman
School of Pharmacy at the University of North Carolina – Chapel Hill, U.S.A. He had his Bachelor of Pharmacy degree from National
Taiwan University and his Master degree in Health Policy and Administration in Washington State University U.S.A. Dr. Wu graduated
from University of Michigan U.S.A., College of Pharmacy in 2010 and had his Ph.D. degree in Clinical, Social, and Administrative
Pharmacy.
Dr. Wu’s research interests focus on medication-related health outcomes, including medication adherence, persistence, and health
resource utilization among patients with chronic diseases. With multidisciplinary training in pharmacy, health policy and
administration, and health services research, Dr. Wu has extensive experience working with large health claims data and complex
sample survey data to conduct pharmaceutical outcomes research. He is familiar with administrative claims data such as MarketScan®
Commercial Claims data, MarketScan® Multi-States Medicaid Administrative data, and Humana Medicare and Commercial Claim Data
as well as complex survey data such as the Medical Expenditure Panel Survey (MEPS), National Comorbidity Survey-Replication (NCS-R),
and National Health Interview Survey (NHIS).
Prior to his current appointment, Dr. Wu was a Human/UNC Pharmaceutical Outcomes Post-Doctoral Research Fellow in the Eshelman
School of Pharmacy at the University of North Carolina – Chapel Hill, U.S.A. He had his Bachelor of Pharmacy degree from National
Taiwan University and his Master degree in Health Policy and Administration in Washington State University U.S.A. Dr. Wu graduated
from University of Michigan U.S.A., College of Pharmacy in 2010 and had his Ph.D. degree in Clinical, Social, and Administrative
Pharmacy.

卓爾婕助理教授 Assistant Prof. Er-Chieh Cho, MSc., DPhil.
Molecular Cancer Biology, Translational Medicine, and Nanomedicine
1. Cho EC, Zheng S, Munro S, Liu G, Carr SM, Moehlenbrink J, Lu YC, Stimson L, Khan O, Konietzny R,
McGouran J, Coutts AS, Kessler B, Kerr DJ, Thangue NB. Arginine Methylation Controls Growth
Regulation by E2F-1. EMBO J. 2012 Feb 10;31(7):1785-97.
2. Cho EC, Kuo ML, Liu X, Yang L, Hsieh YC, Wang J, Cheng Y, Yen Y. Tumor suppressor FOXO3
regulates
ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients. Oncotarget.
2014 Jul 15;5(13):4834-44.
3. Hsieh YC, Cho EC, Tu SH, Wu CH, Hung CS, Hsieh MC, Su CT, Liu YR, Lee CH, Ho YS, Chiou HY. MSH2
rs2303425 Polymorphism is Associated with Early-Onset Breast Cancer in Taiwan. Ann Surg Oncol.
2017 Feb;24(2):603-610. doi: 10.1245/s10434-016-5168-5.
4. Yang KC, Zheng JH, Chen YL, Lee KC, Cho EC. Carboxyfullerene decorated titanium dioxid
enanomaterials for reactive oxygen species scavenging activities. RSC Adv. 2016(6):53025-53033.
A model of protein arginine
methyltransferase PRMT5-mediated
methylation on E2F1 response
regulation.
Research in our laboratory is focused on molecular cancer biology in translational
medicine and biomedical applications of nanomaterials. The molecular mechanisms of
tumor development has been researched by studying protein post-translational
modifications of key cellular regulators such as E2F1 and p53; the transcriptional
regulation of CREB in leukemogenesis has also been studied; tumorigenesis in colon
cancer is currently under investigation in our group; our laboratory is also cooperating
with scientists in material science and bioinformatics. Undergoing projects include
evaluation and development of different nanomaterials in biomedical application.
Research in our laboratory is focused on molecular cancer biology in translational
medicine and biomedical applications of nanomaterials. The molecular mechanisms of
tumor development has been researched by studying protein post-translational
modifications of key cellular regulators such as E2F1 and p53; the transcriptional
regulation of CREB in leukemogenesis has also been studied; tumorigenesis in colon
cancer is currently under investigation in our group; our laboratory is also cooperating
with scientists in material science and bioinformatics. Undergoing projects include
evaluation and development of different nanomaterials in biomedical application.
E2F1 level PRMT5 level
E2F1 methylated and
transcription suppressed
E2F1-induced apoptosis
increased
a. Biomarker development
b. Tumorigenesis of colon cancer
c. Toxicology study and development of nanomaterials in biomedical applications

Representative publications
a. Interprofessional Care
b. Chronic Disease Management
c. Evaluation of Pharmacy Services
d. Factors Influencing Medication Use
e. Pharmacy Education
1. Patterson BJ, Chang EH, Witry MJ, Garza OW, Trewet CB. Pilot evaluation of a continuing professional development tool for
developing leadership skills. Research in Social & Administrative Pharmacy. 2013 Mar-Apr;9(2):222-9.
2. Doucette WR, Chang EH, Pendergast JF, Wright KB, Chrischilles EA, Farris KB. Development and initial assessment of the
Medication Use Self Evaluation (MUSE) Tool. Clinical Therapeutics. 2013 Mar;35(3):344-50.
3. Patterson BJ, Garza OW, Witry MJ, Chang EH, Letendre DE, Trewet CB. A leadership elective course developed and taught by
graduate students. American Journal of Pharmaceutical Education. 2013 Dec;77(10):223.
Dr. Chang’s research group focuses on pharmacy practice and education. We
believe that practice-based research is important for expanding pharmacist roles and
advancing the pharmacy profession. In particular, we are interested in understanding
patient perceptions of medication use and evaluating interventions to improve patient
outcomes. Our group specializes in qualitative methods and mixed quantitative and
qualitative methods. Recent projects involve medication adherence, health literacy,
medication reconciliation, and controlled drugs policy in Taiwan.
In addition to the faculty appointment, Dr. Chang serves as the Deputy Director of
Department of Pharmacy, Taipei Municipal Wanfang Hospital (Managed by Taipei
Medical University, TMU). Prior to arriving at TMU, Dr. Chang received her Ph.D. in
Pharmaceutical Socioeconomics from the University of Iowa and Doctor of Pharmacy
from the Ohio State University.
Dr. Chang’s research group focuses on pharmacy practice and education. We
believe that practice-based research is important for expanding pharmacist roles and
advancing the pharmacy profession. In particular, we are interested in understanding
patient perceptions of medication use and evaluating interventions to improve patient
outcomes. Our group specializes in qualitative methods and mixed quantitative and
qualitative methods. Recent projects involve medication adherence, health literacy,
medication reconciliation, and controlled drugs policy in Taiwan.
In addition to the faculty appointment, Dr. Chang serves as the Deputy Director of
Department of Pharmacy, Taipei Municipal Wanfang Hospital (Managed by Taipei
Medical University, TMU). Prior to arriving at TMU, Dr. Chang received her Ph.D. in
Pharmaceutical Socioeconomics from the University of Iowa and Doctor of Pharmacy
from the Ohio State University.
張雅惠助理教授 Assistant Prof. Elizabeth H. Chang
Clinical, Social and Administrative Pharmacy

鄭桂如講師 Lecturer Kuei-Ju Cheng, Ph.D.
Research AreasResearch Areas
Clinical research and projects with focus on:
a.Cost saving on pharmacist interventions
b.Medication utilization evaluations
c.Development of informatics systems in hospital pharmacy
d.Development of informatics systems in pharmacy education
1. Yu-Hsuan Yen , Li-Na Kuo , Min-Huei Hsu , Yu-Chuan Li , Kuei-Ju Cheng. “Evaluation of
the electronic adverse drug event management system.” Journal of Experimental and
Clinical Medicine(JECM). 2010 Dec ； 2 （ 6 ）： 287-291
2. Yu-Hsuan Yen, Hsiang-Yin Chen, Leu Wuan-Jin, You-Meei, Lin, Wan Chen Shen, Kuei-Ju
Cheng. “Clinical and Economic Impact of a Pharmacist-managed IV-to-PO Conversion Service
for Levofloxacin in Taiwan.” International Journal of Clinical Pharmacology and Therapeutics.
2012; 50(2): 136-141
3. Yu-Ting Yeh*, Hsiang-Yin Chen*, Kuei-Ju Cheng, Su-An Hou,Yu-Hsuan Yen, Chien-Tsai Liu.
“Evaluating an Online Pharmaceutical Education System for Pharmacy Interns in Critical Care
Settings”Computer Methods and Programs in Biomedicine

石榴皮
紅球薑
蛇床子
威靈仙
白朮
鹿茸
紅花大黃
王靜瓊教授 Prof. Ching-Chiung Wang
Pharmacology of Traditional Chinese Medicine
Develop the new botanical drugs based on theory of TCM, phytochemistry and pharmacology
1. Tseng, S.H.; Sung, C.H; Chen, L. G.; Laie, Y. J.; Chang, W. S.; Sung, H. C.;
Wang, C. C.*
Journal of Ethnopharmacology. 2014, 151, 352-360.
2. Lee Y.W., Chen T.L., Shih Y.R. Vernon, Tai C.L., Chang C.C., Liang H.H.,
Tseng S.H., Chien S.C., Wang C.C.*
Cancer, 2014, 1338-1344.
3. Chen LG, Jan YS, Tsai PW, Norimoto H, Michihara S, Murayama C, Wang
C. C.*. J Agric Food Chem, 2016, 64(11):2254-62.
4. Chen LG, Su PJ, Tsai PW, Yang LL, Wang C. C.*. Planta Medica. 2017
(83):151-157.
a. Investigate the processed methods of TCM
b. Investigate the philosophy of TCM prescription
c. Investigate the pharmacology of TCM
The above herbals were studies in our laboratory.
Our researches are focus on evidence-based traditional Chinese medicines
(TCM) and then translate the findings to biopharmaceutical products. Firstly, the
processed methods of TCM are explored. We investigate the correlation of
phytochemistry and pharmacology after processed-TCM and expect to control the
quality of the TCM. Secondly, the philosophies of TCM prescriptions are explored.
Most TCM prescriptions include more than four herbs, and each herb has its
special function. Phytochemicals contained in TCM prescriptions were used to
discuss the clinical application and expect to understand the reasons of TCM
prescription compositions. Finally, according to the findings, we hope we can
create a new botanical drug or a new TCM prescription. Currently, our important
missions are find application of the TCM on arthritis, gastric ulcer, acnes,
osteoporosis, and chemoprevention.
Our researches are focus on evidence-based traditional Chinese medicines
(TCM) and then translate the findings to biopharmaceutical products. Firstly, the
processed methods of TCM are explored. We investigate the correlation of
phytochemistry and pharmacology after processed-TCM and expect to control the
quality of the TCM. Secondly, the philosophies of TCM prescriptions are explored.
Most TCM prescriptions include more than four herbs, and each herb has its
special function. Phytochemicals contained in TCM prescriptions were used to
discuss the clinical application and expect to understand the reasons of TCM
prescription compositions. Finally, according to the findings, we hope we can
create a new botanical drug or a new TCM prescription. Currently, our important
missions are find application of the TCM on arthritis, gastric ulcer, acnes,
osteoporosis, and chemoprevention.
Integration of three ancient purgative formulas with modern scientific
evidence-based explains.

侯文琪教授 Prof. Wen-Chi Hou
Functionality of protein, peptides, and natural products in vitro/in vivo
ORCID iD:0000-0002-9565-7018 (E-mail: wchou@tmu.edu.tw)
ProtocolsProtocols
a. Antioxidant/anti-aging activity in vitro and in vivo
b. Prevention against metabolic syndrome disorders
1. Lin, Y. S., Chen, C. R., Wu, W. H., Wen, C. L., Chang, C. I,* Hou, W. C.* 2015. Anti-a-
glucosidase and anti-dipeptidyl peptidase-IV activities of extracts and purified
compounds from Vitis thunbergii var. taiwaniana. J. Agric. Food Chem. 63, 6393-6401.
2. Lin, S. Y., Huang, G. C., Hsieh, Y. Y., Lin, Y. S., Han, C. H., Wen, C. L., Chang, C. I,* Hou, W.
C.* 2015. Vitis thunbergii var. taiwaniana extracts and purified compounds ameliorate
obesity in high-fat diet-induced obese mice. J. Agric. Food Chem. 63, 9286-9294.
3. Han, C. H., Lin, Y. S., Lee, T. L., Liang, H. J.,* and Hou, W. C.* 2014. Asn-Trp dipeptides
improve the oxidative stress and learning dysfunctions in D-galactose-induced BALB/c
mice. Food & Funct. 5, 2228-2236.
4. Han, C. H., Lin, Y. F., Lin, Y. S., Lee, T. L., Huang, W. J., Lin, S. Y.*, and Hou, W. C.* 2014.
Effects of yam tuber protein, dioscorin, on attenuating oxidative status and learning
dysfunction in D-galactose-induced BALB/c mice. Food Chem. Toxicol. 65, 356-363.
5. Han, C. H., Liu, J. C., Fang, S. U., and Hou, W. C.* 2013. Antioxidant activities of the
synthesized thiol-contained peptides derived from computer-aided pepsin hydrolysis of
yam tuber storage protein, dioscorin. Food Chem.138, 923-930.
DD-galactose-induced oxidative damage and-galactose-induced oxidative damage and
agingaging
Control : galactose-
induced
Blank: untreated
one

偉展黃副教授 Prof. Wei-Jan Huang
Natural product and Medicinal chemistry
Synthesis and evaluation of natural product–based compounds with biological
activities
a. Knowledge-based drug design
b. Computation chemistry-aided drug design
c. Total synthesis and structure modification of naturally occurring
compounds
Histone deacetylases (HDACs) are a family of enzymes for regulating gene
transcription and play a crucial role in biological process and diseases. Our
research focuses on developing pan and isoform-selective HDAC inhibitors
through combination of synthetic medicinal chemistry, enzyme screening panels
and molecular modeling. We are also interested in exploration for small
molecules targeting neuronal Tourret syndrome and Alzheimer disease. Some
resulting compounds and their application have been filed patent.
Histone deacetylases (HDACs) are a family of enzymes for regulating gene
transcription and play a crucial role in biological process and diseases. Our
research focuses on developing pan and isoform-selective HDAC inhibitors
through combination of synthetic medicinal chemistry, enzyme screening panels
and molecular modeling. We are also interested in exploration for small
molecules targeting neuronal Tourret syndrome and Alzheimer disease. Some
resulting compounds and their application have been filed patent.
1. Chao, S. W.; Su, M. Y.; Chiou L. C.; Chen, L. C.; Chang, C. I*; Huang, W. J.* J.
Nat. Prod. 2015, 78, 1969-1976.
2. Lin, C. M., Lin, Y. T., Lin, R. D., Huang, W. J.*, Lee, M. H. ACS Chem.
Neurosci. 2015, 20, 716-724.
3. Huang, W. J.*; Wang, Y. C.; Chao, S. W.; Yang, C. Y.; Chen, L. C.; Lin, M. H.;
Hou, W. C.; Chen, M. Y.; Lee, T. L.; Yang, P.; Chang, C. I * ChemMedChem
2012, 7, 1815-1824

林若凱助理教授 Assistant Prof. Ruo-Kai Lin
Epigenetic and Molecular oncology research
New anti-cancer drug development
a. Identification of cancer associated biomarker
b. Discovery of new anti-cancer targets
c. Establishment of high-throughput drugs screening platform
Research in our laboratory is focused on the identification of new
important anti-cancer drug targets from clinical breast and colon
tumors. We further try to develop new target specific anti-cancer
drugs through establishment of high-throughput drugs screening
platform. We have identified antroquinonol D induces DNA
demethylation and the recovery of multiple tumor suppressor genes,
while leading breast cancer cell death and inhibiting metastatic
potential.
Research in our laboratory is focused on the identification of new
important anti-cancer drug targets from clinical breast and colon
tumors. We further try to develop new target specific anti-cancer
drugs through establishment of high-throughput drugs screening
platform. We have identified antroquinonol D induces DNA
demethylation and the recovery of multiple tumor suppressor genes,
while leading breast cancer cell death and inhibiting metastatic
potential.
1. Chang-Lin Hsieh, Hon-Ping Ma and Ruo-Kai Lin* et. al. Alterations in Histone Deacetylase 8 Lead to Cell Migration and Poor Prognosis
in Breast Cancer. Life Sciences. (2016, Accepted).
2. Sheng-Chao Wang and Ruo-Kai Lin* et. al. Antroquinonol D, isolated from Antrodia camphorate, with DNA demethylation and anti-
cancer potential. Journal of Agricultural and Food Chemistry. 2014 (62):5625-5635.
3. Ruo-Kai Lin, and Yi-Ching Wang* et. al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and
tumor suppressor gene hypermethylation in mice and lung cancer patients..The Journal of clinical investigation. 2010 (120):521-532.
4. Ruo-Kai Lin, and Yi-Ching Wang* et. al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase 1 overexpression in lung
cancer. Cancer research. 2010 (70):5807-5817.

莊國祥助理教授 Assistant Prof. Kuo-Hsiang Chuang
Antibody Engineering, Reporter Gene/Noninvasive Imaging, Immunology
a. Bi-specific antibody to one-step expand and arm T
cells for selective tumor therapy
b. Bi-specific antibody to enhance tumor killing
efficacy of mPEG conjugated drugs
c. Generate an endogenous reporter transgenic
mouse to track cell fates and transplant survival
d. Herbal extracts to reduce the side effects of clinical
chemotherapy
1. Hao WR, Chen M, Chen YJ, Su YC, Cheng CM, Hsueh HY, Kao AP, Hsieh YC, Chang J, Tseng MY, Chuang KH*. Poly-protein G-expressing bacteria
enhance the sensitivity of immunoassays. Scientific Reports 2017 (Accepted). IF: 5.228
2. Su YC, Burnouf PA, Chuang KH, Chen BM, Cheng TL, Roffler SR. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple
negative breast cancer therapy. Nature communications 2017 (Accepted). IF: 11.329
3. Hsieh YC, Cheng TC, Wang HE, Li JJ, Lin WW, Huang CC, Chuang CH, Wang YT, Wang JY, Roffler SR, Chuang KH*, Cheng TL*. Using anti-
poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Scientific Reports 2016 Dec 19;6:39119. IF: 5.228
4. Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, Wei PK, Cheng TL, Roffler SR. Engineering Chimeric Receptors To Investigate the
Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. ACS Nano. 2016 Jan 26;10(1):648-62. IF: 13.334
5. Chuang KH, Kao CH, Roffler SR, Lu SJ, ChengTC, Wang YM, Chuang CH, Hsieh YC, Wang YT, Wang JY, Weng KY, and Cheng TL. Development of an
Anti-Methoxy Polyethylene Glycol (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules 2014 Sep;
47(19) 6880-8. IF: 5.554
6. Chuang KH, Hsieh YC, Chiang IS, Chuang CH, Kao CH, Cheng TC, Wang YT, Lin WW, Chen BM, Roffler SR, Huang MY, and Cheng TL. High-throughput
sorting of the highest producing cell via a transiently protein-anchored system. PLOS ONE 2014 Jul; 9(7):e102569. IF: 3.234
(1)
(2)

李美賢教授 Prof. Mei-Hsien Lee
Pharmacognosy
Chinese herbal medicine
Chemistry and biological activity of natural products
Representative Publications:
1.YH Huang, TH Lee, KJ Chan, FL Hsu, YC Wu, MH Lee*. Journal of Dermatological Science 2008; 49: 115-123.
2.YP Lin, TY Chen, HW Tseng, MH Lee*, ST Chen. Phytochemistry 2009; 70: 1173-1181.
3.YP Lin, TY Chen, HW Tseng, MH Lee*, ST Chen*. Phytochemistry 2012, 84: 102-115.
4.RD Lin, MC Chen, YL Liu, YT Lin, MK Lu, FL Hsu, MH Lee*. International Journal of Molecular Sciences 2015, 16, 28598-28613.
5.CM Lin, YT Lin, RD Lin, WJ Huang, MH Lee*. ACS Chemical Neuroscience 2015, 6, 716-724.
6.MH Lee, FL Hsu, YLLiu. Extracts and compounds for inhibiting tyrosinase activity 2010 (US 7,838,049 B2)
7.MH Lee. Use of Uraria in promoting osteogenesis or providing neuroprotection. 2015 (US9044476B2)
a. The analysis and extraction/purification/identification of Chinese herbal medicines/prescriptions or Taiwan native plants
b. To establish several platforms of aging-related diseases, including osteoporosis, neurodegenerative diseases, skin aging and
photoaging, for phytohemicals/nutraceuticals/drugs screening
c. Preventive medicines
d. The development of external herbal preparations

李佳蓉助理教授 Assistant Prof. Chia-Jung Lee,RPh, Ph.D.
Pharmacology and Pharmacokinetic Laboratory
Clinical Drug Discovery of Chinese Herbal Medicine
a. Bio-assay guided fraction of TCM.
b. Pharmacological study of TCM, such as anti-
inflammation, anti-arthritis and anti-acne effects.
c. Pharmacokinetics analysis of traditional Chinese
medicines (TCM) by microdialysis technology and
HPLC/MS/MS analysis.
d. TCM-related researches from National Health
Insurance Research Database.
1. Lee CJ, Chen LG, Liang WL, Wang CC. Multiple Activities of Punica granatum Linne against acne vulgaris.
International Journal of Molecular Sciences, 2017, Jan 12;18(1).
2. Chien TY, Huang SK, Lee CJ, Tsai PW, et al., International Journal of Molecular Sciences, 2016, 17, pii: E249.
3. Huang GC, Chen SY, Tsai PW, Ganzon JG, Lee CJ, et al., Drug Design, Development and Therapy. 2016, 10,
949-57.
4. Lee CJ, Hsueh TY, Lin LC, Tsai TH. Biomedical Chromatography, 2014, 28, 901-6.
5. Tsai CF, Wang KT, Chen LG, Lee CJ, et al., Journal of Medicinal Food, 2014, 17, 479-86.
6. Lee CJ, Wu YT, Hsueh Thomas Y, Lin LC, et al., Biomedical Chromatography, 2014, 28, 630-6.

陳美全助理教授 Assistant Prof. Mei-Chuan Chen
Cancer Pharmacology, Cancer Biology, Signal transduction

張偉嶠教授 Prof. Wei-Chaio Chang
牛津大學生理解剖遺傳學研究所博士暨 (University of Oxofrd, DPhil)
成功大學藥理學研究所碩士 (National Cheng Kung University, MSc)
台北醫學大學藥學系學士 (Taipei Medical University, BS)
Pharmacogenomics and Personalized Medicine
a.Genetic characterization of gene signatures to establish personalized therapy
b.Immune repertoire sequencing and bioinformatics analysis for drug
responsiveness
This laboratory is to conducting research to determine how we could utilize human genetic
information to personalized therapy. The current study in our laboratory is focusing on
inflammatory/autoimmune diseases. Through genomic analysis and data mining, we expect
to identify useful biomarkers (genetic polymorphisms/immune repertoire) that could be
translated into clinical tools. We hope the genetic information identified from our population
help us to improve clinical diagnosis and to facilitate the development of therapy.
This laboratory is to conducting research to determine how we could utilize human genetic
information to personalized therapy. The current study in our laboratory is focusing on
inflammatory/autoimmune diseases. Through genomic analysis and data mining, we expect
to identify useful biomarkers (genetic polymorphisms/immune repertoire) that could be
translated into clinical tools. We hope the genetic information identified from our population
help us to improve clinical diagnosis and to facilitate the development of therapy.
Three Dimensional Calcium Wave
Genetic Profiles and Drug responses
Representative Publications *corresponding authors
1.Wong HS, Chang CM, Liu X, Huang WC, Chang WC*. Characterization of cytokinome landscape for
clinical responses in human cancers. Oncoimmunology. 2016
2.Wong HS, Juan YS, Wu MS, Zhang YF, Hsu YW, Chen HH, Liu WM and Chang WC*. Integrative
bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and
guide drug discovery. Oncotarget. 2015
3.Wong HS and Chang WC*. Correlation of clinical features and genetic profiles of stromal
interaction molecule 1 (STIM1) in colorectal cancers. Oncotarget. 2015
4.Chang WC, Wu SL, Huang WC, Hsu JY, Chan SH, Wang JM, Tsai JP, Chen BK. PTX3 gene activation
in EGF-induced head and neck cancer cell metastasis. Oncotarget. 2015
5.Juan YS, Lee YL, Long CY, Wong JH, Jang MY, Lu JH, Wu WJ, Huang YS, Chang WC*, Chuang SM*.
Translocation of NF-κB and expression of cyclooxygenase-2 are enhanced by ketamine-induced
ulcerative cystitis in rat bladder. Am J Pathol. 2015
6.Wang JY, Sun J, Huang MY, Wang YS, Hou MF, Sun Y, He H, Krishna N, Chiu SJ, Lin S, Yang S*,
Chang WC*. STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2
expression. Oncogene. 2015

韓嘉莉助理教授 Assistant Prof. Chia-Li Han
Individualized Tissue Membrane Proteomics
Mass Spectrometry-based Proteogenomics Analysis
a. Onco-proteogenomics investigation of cancer-specific mutated proteins
b. Development of MS-based technologies for individualized membrane proteomics analysis
We aim to develop mass spectrometry (MS)-based analytical strategies for quantitative analysis
of membrane proteomics as well as proteogenomics analysis of cancer-specific mutations. The
developed methodologies are applied in clinical specimens to discover potential biomarkers for
diagnosis and prognosis purposes.
We aim to develop mass spectrometry (MS)-based analytical strategies for quantitative analysis
of membrane proteomics as well as proteogenomics analysis of cancer-specific mutations. The
developed methodologies are applied in clinical specimens to discover potential biomarkers for
diagnosis and prognosis purposes.
1.Tsai MT, Chen YJ, Chen CY, Tsai MH, Han CL, Chen YJ, Mersmann HJ, Ding ST5, J
Nutr. 147: 293-303 (2017)
2.Chen CL, Wu YY, Lin CF, Kuo CF, Han CL, Wang SY, Chuang WJ, Chen CY, Wu JJ,
Tsai PJ, Liu CC, Lin YS, Scientific Reports 6, 26026 (2016)
3.Che TF, Lin CW, Wu YY, Chen YJ, Han CL, Chang YL, Wu CT, Hsiao TH, Hong TM,
Yang PC, Oncotarget, 6, 37349-37366 (2015).
4.Chang CW, Chen YS, Chou SH, Han CL, Chen YJ, Yang CC, Huang CY, Lo JF*,
Cancer Res., 74, 1-15 (2014)
5.Huang TK, Han CL, Lin SI, Chen YJ, Tsai YC, Chen YR, Chen JW, Lin WY, Chen PM,
Liu TY, Chen YS, Sun CM and Chiou TJ*, Plant Cell, 25, 4044-4060 (2013)
6.Chiang SC, Han CL, Yu KH, Chen YJ, Wu KP* PLoS ONE, 8, e81079. (2013)
7.Han CL, Chen JS, Chan EC, Wu CP, Yu KH, Chen KT, Tsou CC, Tsai CF, Chien CW,
Kuo YB, Lin PY, Yu JS, Hsueh C, Chen MC, Chan CC, Chang YS, Chen YJ*, Mol. Cell.
Proteomics 10, 1–15 (2011)
8.Han CL, Chien CW, Chen WC, Chen YR, Wu CP, Li H, and Chen YJ*, Mol. Cell.
Proteomics. 7, 1983–1997 (2008)

林恒教授 Prof. Heng Lin
Heart, kidney and antiobesity pathophysiology and drug development
a. Discovery and development of small molecules towards anti obesity
b. Development of small molecule for coating on stent for heart and kidney
c. Development a microRNA- SPR fast urinary detection system for kidney injury
d. Explore the HAX-1 gene function in heart and kidney
Research in our laboratory is focused on the design new chemical single compound for inhibition of obesity or increasing heart
or kidney function. One newly synthesized compound showed significant antiobesity on mice models. In addition, we also
construct a kidney, heart, endothelium and smooth muscle cell specific knock out mice of HAX-1 gene for studying
pathophysiology role of HAX-1 on theses organ.
Research in our laboratory is focused on the design new chemical single compound for inhibition of obesity or increasing heart
or kidney function. One newly synthesized compound showed significant antiobesity on mice models. In addition, we also
construct a kidney, heart, endothelium and smooth muscle cell specific knock out mice of HAX-1 gene for studying
pathophysiology role of HAX-1 on theses organ.
pGL4-Axx 3T3-L1 stable clone
Screening
Axx -/- mice
WT mice
Axx Axx
Axx/CRE
ChREBP
Axx Axx
PGC1α
UCP1?
+ Axx inducer
lean lean
Representative publications
1. Chen HH, Lan YF, Li HF, Cheng CF, Lai PF, Li WH, Lin H*. Sci Rep.
2016 Jun; 6(14): 27945-59.
2. Chen HH, Lai PF, Lan YF, Cheng CF, Zhong WB, Lin YF, Chen TW, Lin
H*. J Cell Physiol. 2014 Sep; 229 (9):1202-11.
3. Lin H, Li HF, Chen HH, Lai PF, Juan SH, Chen JJ, Cheng CF. Mol
Pharmacol. 2014 May; 85(5): 682-91.
4. Lin H, Li HF, Lian WS, Chen HH, Lan YF, Lai PF, Cheng CF. Circ J.
2013 Jul; 77(10): 2586-95.
5. Lin H, Lian WS, Chen HH, Lai PF, Cheng CF. Mol Pharmacol. 2013
Aug; 84(2): 275-85.
6. Lan YF, Chen HH, Lai PF, Cheng CF, Huang YT, Lee YC, Chen TW, Lin
H*. J Am Soc Nephrol. 2012 Dec; 23(12): 2012-23.
7. Cheng CF, Lian WS, Chen SH, Lai PF, Li HF, Lan YF, Cheng WT, Lin
H*. J Cell Physiol. 2012 Jan; 227(1): 239-49.
8. Cheng CF, Lin H*. Toxicol Mech Methods. 2011 May; 21(4): 362-6.

北醫藥學院教師研究專長簡介

More Related Content

What's hot

Similar to 北醫藥學院教師研究專長簡介

Recently uploaded

北醫藥學院教師研究專長簡介